TP53 and neoplasm: Because approximately half of all cancers have a defective p53 tumour suppression function [19], CHK2 inhibition could selectively reduce p53-mediated apoptosis in normal tissue and therefore mitigate the side-effects of such therapies in patients with this profile [4], [20].